Neboglamine (CR-2249, XY-2401) hydrochloride is an orally active NMDA receptor glycine site positive modulator that can be used in schizophrenia research.
Neboglamine hydrochloride (s.c. or p.o., 0.3-30 mg/kg) can regulate neuronal activity in brain regions and inhibit PCP-induced hypermobility in rats[1].
References:
[1]. Riccardo Chiusaroli, et al. Antipsychotic-like effects of the N-methyl-D-aspartate receptor modulator neboglamine: an immunohistochemical and behavioural study in the rat. Pharmacol Res. 2010 May;61(5):430-6.
















